Element Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Element Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,265	Closed	-$2.7M	–	111
2025 Q1	$2.7M	Buy	+4,265	New	+$2.93M	0.67%	72
2019 Q2	–	Sell	-17,531	Closed	-$7.2M	–	625
2019 Q1	$7.2M	Sell	17,531 -15,111	-46%	-$6.22M	0.22%	80
2018 Q4	$12.2M	Sell	32,642 -35,875	-52%	-$13.1M	0.35%	54
2018 Q3	$27.7M	Buy	+68,517	New	+$26.1M	0.55%	29

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Element Capital Management's REGN Position: Q2 2025 in Review

Element Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 4,265 shares — an estimated $2.7M sold.

Element Capital Management first reported a position in REGN in Q3 2018 and held it in 4 quarters. The position peaked at $27.7M in Q3 2018. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Element Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Element Capital Management sold 4,265 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $2.7M.
Element Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2018 and held it in 4 quarters.
Element Capital Management's Regeneron Pharmaceuticals position peaked at $27.7M in Q3 2018.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Element Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.